title: Bortezomib and high-dose melphalan conditioning for stem cell transplantation for AL amyloidosis: a pilot study.
authors.forename: Vaishali
authors.initials: V
authors.lastname: Sanchorawala
authors.forename: Karen
authors.initials: K
authors.lastname: Quillen
authors.forename: J Mark
authors.initials: JM
authors.lastname: Sloan
authors.forename: Nancy T
authors.initials: NT
authors.lastname: Andrea
authors.forename: David C
authors.initials: DC
authors.lastname: Seldin
mesh_terms: D000368:Aged; D000686:Amyloidosis / Q000628:therapy* / Q000652:urine; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D001897:Boronic Acids / Q000008:administration & dosage* / Q000009:adverse effects; D000069286:Bortezomib; D005260:Female; D006801:Humans; D008297:Male; D008558:Melphalan / Q000008:administration & dosage* / Q000009:adverse effects; D008875:Middle Aged; D019653:Myeloablative Agonists / Q000008:administration & dosage* / Q000009:adverse effects; D010865:Pilot Projects; D011719:Pyrazines / Q000008:administration & dosage* / Q000009:adverse effects; D033581:Stem Cell Transplantation; D019172:Transplantation Conditioning / Q000379:methods*; D014182:Transplantation, Autologous
chemical_list: D000970:Antineoplastic Agents; D001897:Boronic Acids; D019653:Myeloablative Agonists; D011719:Pyrazines; D000069286:Bortezomib; D008558:Melphalan